Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ensysce Biosciences, Inc.ENSC · Entity 8108 | Director | June 23, 2022 | June 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ensysce Biosciences, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2032-06-23 | Direct | 35,000 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 20,000 · Balance 35,000 F1: On June 23, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 23, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2022 Filed Jun 27, 2022 17:38 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 20,000 | Not disclosed Strike: $0.43 | Not disclosed |
DisclosureSEC source: 0001493152-22-017873 · ownership.xml · derivative · entry 1 Rosebraugh Curtis · CIK 0001869847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · security: On June 23, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. F1 · price: On June 23, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. F1 · derivative.exercise_date: On June 23, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. Read SEC document |
| February 04, 2022 Filed Feb 4, 2022 15:19 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 20,000 | Not disclosed Strike: $3.13 | Not disclosed |
DisclosureSEC source: 0001493152-22-003210 · ownership.xml · derivative · entry 1 Rosebraugh Curtis · CIK 0001869847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-04 F1 · security: On February 4, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022. F1 · price: On February 4, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022. F1 · derivative.exercise_date: On February 4, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.